Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 10/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810091 | 0.87 | RAB9A (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL4814882 | 0.86 | NPSR1 (0.33) | CYP3A4 | |
| SCHEMBL27655543 | 0.80 | F10 (0.36) | ALDH1A1LMNASMN1; SMN2CASP6MEN1 | |
| SCHEMBL11294177 | 0.80 | ALDH1A1 (0.33) | ALDH1A1LMNASMN1; SMN2CASP6MEN1 | |
| SCHEMBL4813014 | 0.79 | PTPN2 (0.41) | ALDH1A1LMNAKMT2A | |
| SCHEMBL4808456 | 0.79 | KCNH2 (0.43) | LMNASMN1; SMN2CYP3A4CYP2D6MEN1 | |
| SCHEMBL4812517 | 0.79 | AKT1 (0.37) | ALDH1A1LMNAHSD17B10AKT1 | |
| SCHEMBL24565371 | 0.79 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD17B10AKT1SMN1; SMN2 | |
| SCHEMBL4811203 | 0.79 | F10 (0.41) | ALDH1A1LMNAHSD17B10AKT1ACHE | |
| SCHEMBL4812872 | 0.78 | LMNA (0.35) | ALDH1A1LMNAHSD17B10AKT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | ALDH1A1 71/4885LMNA 2659/4885HSD17B10 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.